Non-Alcoholic Steatohepatitis Pipeline Drugs 2023 (Updated), FDA Approvals, Clinical Trials, MOA, ROA | Madrigal, Cirius Therapeutics, AstraZeneca, Ionis, NorthSea Therapeutics, Rivus, and others

June 26 05:32 2023
Non-Alcoholic Steatohepatitis Pipeline Drugs 2023 (Updated), FDA Approvals, Clinical Trials, MOA, ROA | Madrigal, Cirius Therapeutics, AstraZeneca, Ionis, NorthSea Therapeutics, Rivus, and others

(Albany, United States) As per DelveInsight’s assessment, globally, the Non-Alcoholic Steatohepatitis pipeline constitutes 100+ key companies continuously working towards developing 150+ Non-Alcoholic Steatohepatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The Non-Alcoholic Steatohepatitis pipeline report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, Non-Alcoholic Steatohepatitis NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Non-Alcoholic Steatohepatitis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Key Takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report

  • DelveInsight’s Non-Alcoholic Steatohepatitis Pipeline analysis depicts a robust space with 100+ active players working to develop 150+ pipeline treatment therapies.
  • The leading Non-Alcoholic Steatohepatitis Companies are working in the market include Madrigal Pharma, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, TaiwanJ Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune, Inc., Sciwind Biosciences, SCOHIA PHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, Bird Rock Bio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Life sciences, Gmax Biopharm, Albireo Pharma, InorbitTX, Viking Therapeutics, Ildong Pharmaceutical, Thoth Science, and others
  • Emerging Non-Alcoholic Steatohepatitis Pipeline Therapies in the various stages of development include hydroxychloroquine, Berberine, Digoxin tablet, MK-3655, EDP-305 Dose 2, Atorvastatin, L-Carnitine, Ursodeoxycholic Acid, MRI-PDFF, and others
  • On February 2023, Corcept Therapeutics has announced drug named MRI-PDFF in the market. This optional sub study is a part of the phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). This optional sub study is a part of the phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH).
  • On April 2023, Merck Sharp & Dohme LLC has announced drug named MK-3655 in the market by the phase 2. This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.
  • On February 2023, Beicheng Sun, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has announced drug named Digoxin tablet in the market of phase 2. The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.
  • On March 2023, National Taiwan University Hospital has announced drug named hydroxychloroquine in the market.

 

Non-Alcoholic Steatohepatitis Overview

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells.

 

For further information, refer to the detailed Non-Alcoholic Steatohepatitis Unmet Needs, click here for Non-Alcoholic Steatohepatitis Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Non-Alcoholic Steatohepatitis Emerging Drugs Profile

  • Resmetirom: Madrigal Pharmaceuticals
  • MSDC-0602K: Cirius Therapeutics
  • ION224: Ionis Pharmaceuticals
  • HU 6: Rivus Pharmaceuticals
  • HTD 1801: HighTide Biopharma
  • EDP-305: Enanta Pharmaceuticals

 

Non-Alcoholic Steatohepatitis Pipeline Therapeutics Assessment

There are approx. 130+ Non-Alcoholic Steatohepatitis companies which are developing the therapies for Nonalcoholic Steatohepatitis. The Non-Alcoholic Steatohepatitis companies which have their Nonalcoholic Steatohepatitis drug candidates in the most advanced stage, i.e. phase III include, Madrigal Pharmaceuticals.

 

Request a sample and discover the recent advances in Non-Alcoholic Steatohepatitis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Non-Alcoholic Steatohepatitis Drugs and Companies

  • MK-3655: Merck Sharp & Dohme LLC
  • EDP-305 Dose 1: Enanta Pharmaceuticals Inc
  • Atorvastatin: Tehran University of Medical Sciences
  • MRI-PDFF: Corcept Therapeutics
  • Hydroxychloroquine: National Taiwan University
  • Berberine: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 

 

Non-Alcoholic Steatohepatitis Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Non-Alcoholic Steatohepatitis Therapeutics Market include-

Madrigal Pharma, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, TaiwanJ Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune, Inc., Sciwind Biosciences, SCOHIA PHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, Bird Rock Bio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Life sciences, Gmax Biopharm, Albireo Pharma, InorbitTX, Viking Therapeutics, Ildong Pharmaceutical, Thoth Science, and others.

 

Dive deep into rich insights for drugs for Non-Alcoholic Steatohepatitis Pipeline, click here for Non-Alcoholic Steatohepatitis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Scope of the Non-Alcoholic Steatohepatitis Pipeline Report

  • Coverage- Global
  • Non-Alcoholic Steatohepatitis Companies- Madrigal Pharma, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, TaiwanJ Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune, Inc., Sciwind Biosciences, SCOHIA PHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, Bird Rock Bio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Life sciences, Gmax Biopharm, Albireo Pharma, InorbitTX, Viking Therapeutics, Ildong Pharmaceutical, Thoth Science, and others.
  • Non-Alcoholic Steatohepatitis Therapies- hydroxychloroquine, Berberine, Digoxin tablet, MK-3655, EDP-305 Dose 2, Atorvastatin, L-Carnitine, Ursodeoxycholic Acid, MRI-PDFF, and others.
  • Non-Alcoholic Steatohepatitis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Non-Alcoholic Steatohepatitis Merger and acquisitions, and Licensing Activities @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Table of Content

  1. Introduction
  2. Non-Alcoholic Steatohepatitis Executive Summary
  3. Nonalcoholic Steatohepatitis: Overview
  4. Non-Alcoholic Steatohepatitis Pipeline Therapeutics
  5. Non-Alcoholic Steatohepatitis Therapeutic Assessment
  6. Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Resmetirom: Madrigal Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ION224: Ionis Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AMG 609: Amgen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Nonalcoholic Steatohepatitis Key Companies
  21. Nonalcoholic Steatohepatitis Key Products
  22. Nonalcoholic Steatohepatitis- Unmet Needs
  23. Nonalcoholic Steatohepatitis- Market Drivers and Barriers
  24. Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
  25. Nonalcoholic Steatohepatitis Analyst Views
  26. Nonalcoholic Steatohepatitis Key Companies
  27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment